Drug Database
AM
amlodipine besilate + irbesartan (DSP8153)
✓ ApprovedSumitomo Pharma Co., Ltd. · AGTR1 · Small Molecule
What is amlodipine besilate + irbesartan?
amlodipine besilate + irbesartan is a small molecule developed by Sumitomo Pharma Co., Ltd.. It is approved for therapeutic indications via oral (po).
Drug Profile
| Brand Names | DSP8153 |
| Company | Sumitomo Pharma Co., Ltd. |
| Drug Class | Small Molecule |
| Molecular Target | AGTR1, CACNA1C |
| Route | Oral (PO) |
| Status | Approved |
Sources: ClinicalTrials.gov, Sumitomo Pharma Co., Ltd.
Mechanism of Action
Molecular Targets
amlodipine besilate + irbesartan acts on 2 molecular targets:
| AGTR1 | angiotensin II receptor type 1 (HAT1R, AT1) |
| CACNA1C | calcium voltage-gated channel subunit alpha1 C (CACNL1A1, CACNA1C-IT2) |
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.
Therapeutic Indications
amlodipine besilate + irbesartan is developed for 1 unique indication across 1 therapeutic area.
| Therapeutic Area | Condition | Phase |
|---|---|---|
| Vascular disorders | Hypertension | ✓ Approved |
Related Research Articles
Unable to load articles right now.